文献速递骨质疏松与代谢性骨病

骨质疏松序贯治疗成本-效果分析的系统综述

A systematic review of cost‑effectiveness analyses of sequential treatment for osteoporosis.
PubMed 文献 · Osteoporos Int · 2022-12-17

本研究系统综述并评估骨质疏松序贯治疗的成本-效果分析全文药物经济学研究,检索PubMed、EMBASE(Ovid)、CNKI和万方数据库截至2022年6月17日发表的原创文章,共纳入10篇。与双膦酸盐单药治疗相比,超过75%的研究显示序贯治疗具有成本-效果或占优势,但涉及特立帕肽的序贯治疗除外;涉及阿巴洛肽或罗莫索单抗的序贯治疗相比涉及特立帕肽的序贯治疗具有成本-效果或占优势。

要点

  • 与双膦酸盐单药治疗相比,超过75%的研究显示序贯治疗具有成本-效果或占优势,但涉及特立帕肽的序贯治疗除外。
  • 涉及阿巴洛肽或罗莫索单抗的序贯治疗相比涉及特立帕肽的序贯治疗具有成本-效果或占优势。
  • 涉及阿巴洛肽、罗莫索单抗、地舒单抗和双膦酸盐的序贯治疗可考虑作为高骨折风险骨质疏松的首选方案,而特立帕肽序贯治疗不是成本-效果策略。

核心结论

  • 骨质疏松序贯治疗的成本-效果受多种因素影响。
  • 涉及阿巴洛肽、罗莫索单抗、地舒单抗和双膦酸盐的序贯治疗可考虑作为高骨折风险骨质疏松的首选方案,而特立帕肽序贯治疗不是成本-效果策略。

研究设计与样本

  • 系统综述,检索PubMed、EMBASE(Ovid)、CNKI和万方数据库截至2022年6月17日发表的原创文章。
  • 纳入10篇全文药物经济学研究,采用更新的CHEERS 2022和ESCEO-IOF标准评估质量。

主要发现

  • 与双膦酸盐单药治疗相比,超过75%的研究显示序贯治疗具有成本-效果或占优势,但涉及特立帕肽的序贯治疗除外。
  • 涉及阿巴洛肽或罗莫索单抗的序贯治疗相比涉及特立帕肽的序贯治疗具有成本-效果或占优势。
  • 成本-效果的主要驱动因素包括药物成本、用药持续性和依从性、药物对骨折风险的影响、抵消效应、时间范围和基线骨折风险。
  • 大多数研究在CHEERS(2022)和ESCEO-IOF标准下被评为高质量。

关键数值与推荐

  • 与双膦酸盐单药治疗相比,超过75%的研究显示序贯治疗具有成本-效果或占优势,但涉及特立帕肽的序贯治疗除外。
  • 涉及阿巴洛肽或罗莫索单抗的序贯治疗相比涉及特立帕肽的序贯治疗具有成本-效果或占优势。

临床怎么用

  • 涉及阿巴洛肽、罗莫索单抗、地舒单抗和双膦酸盐的序贯治疗可考虑作为高骨折风险骨质疏松的首选方案。
  • 特立帕肽序贯治疗不是成本-效果策略。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sequential treatment of osteoporosis has been increasingly mentioned in recent years. However, the corresponding systematic review has not been reported. This study aims to systematically review and assess all full-text pharmacoeconomic studies of sequential treatment for osteoporosis. A comprehensive literature search was performed using PubMed, EMBASE (Ovid), CNKI, and Wanfang Database to identify original articles, published before June 17, 2022. The quality of included articles was evaluated by the updated Consolidated Health Economic Evaluation Reporting Standards (CHEERS 2022) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases International Osteoporosis Foundation (ESCEO-IOF). In general, ten articles were included in this review. For the comparison between sequential treatment and bisphosphonate monotherapy, more than 75% of studies demonstrated the sequential treatment was cost-effective or dominant, with the exception of sequential treatment involving teriparatide. When the comparisons occurred between the two sequential treatment groups, the sequential treatments associated with either abaloparatide or romosozumab were cost-effective or dominant compared to the sequential treatment involving teriparatide. Several major key drivers of cost-effectiveness included drug cost, medication persistence and adherence, drug effect on fracture risk, offset effect, time horizon, and baseline fracture risk. The most of studies were identified as high quality in CHEERS (2022) and ESCEO-IOF. The cost-effectiveness of sequential treatment for osteoporosis is influenced by multiple factors. Generally, the sequential treatments involving abaloparatide, romosozumab, denosumab, and bisphosphonates may be considered as the preferred option for osteoporosis with high fracture risk, while the sequential treatment with teriparatide was not a cost-effectiveness strategy. The ESCEO-IOF and CHEER (2022) increase the transparency, comparability, extrapolation, and quality of research, engage patients and the general public in research on health services and policies, and help improve the quality of health technology assessment.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Yu G, Tong S, Liu J, et al. A systematic review of cost‑effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int. 2022. PMID: 36527476. doi:10.1007/s00198-022-06626-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。